"Advocate Secures $100M for Medical Ecstasy Research"
The Multidisciplinary Association for Psychedelic Studies (MAPS) has successfully raised over $100 million through a Series A private stock sale to fund the final phase of regulatory approval for MDMA (Ecstasy) as a treatment for post-traumatic stress disorder (PTSD). This significant financial milestone underscores the growing interest and investment in the therapeutic potential of psychedelics.